Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov;31(11):e16302.
doi: 10.1111/ene.16302. Epub 2024 Apr 15.

What is Alzheimer's disease? An analysis of nosological perspectives from the 20th and 21st centuries

Affiliations
Review

What is Alzheimer's disease? An analysis of nosological perspectives from the 20th and 21st centuries

Nicolas Villain et al. Eur J Neurol. 2024 Nov.

Abstract

Background: Recent US proposals suggest defining Alzheimer's disease (AD) based on β-amyloidosis alone. This sparked debates that echoed historical ones about the significance of brain lesions and clinical phenotype.

Methods: This review covers debates on AD nosology through three key periods: AD's discovery in German-speaking countries in the early 20th century, its redefinition in Anglo-Saxon countries in the 1960s-1980s, and current debates on the biological or clinicobiological definitions of AD. Key players' opinions are focused on.

Results: At the beginning of the 20th century, AD was defined as a clinicopathological entity. Debates arose around the pathological anchor, which included extended neurofibrillary tangles versus neuritic plaques (Alzheimer vs. Fischer) and its association with senile dementia (Kraepelin). In the 1960s-1980s, the debate shifted towards whether AD could be diagnosed using qualitative or quantitative neuropathological features and whether it was a unique process (Terry and Katzman) or had subtypes (Roth). The current definition proposed by the US Alzheimer's Association is based purely on biological β-amyloid abnormalities and represents a double break: from the historical clinicopathological definition of AD and from the historical emphasis on tau or combined tau and β-amyloid high levels of pathology. Conversely, the clinicobiological proposal of the International Working Group remains aligned with historical concepts of AD.

Conclusions: This historical perspective illustrates the unresolved questions surrounding AD pathogenesis, role of lesions, and the clinical phenotype, especially for sporadic cases. The intense nosological debates throughout the history of AD also illustrate the diversity of theoretical frameworks for defining disease in medicine.

Keywords: Alzheimer; definition; disease; history; pathology.

PubMed Disclaimer

Conflict of interest statement

Independent of this work, N.V. received research support from Fondation Bettencourt‐Schueller, Fondation Servier, Union Nationale pour les Intérêts de la Médecine (UNIM), Fondation Claude Pompidou, Fondation Alzheimer, and Fondation pour la Recherche sur l'Alzheimer; travel grants from the Movement Disorder Society, Merz‐Pharma, UCB Pharma, and GE Healthcare SAS; is an unpaid local principal investigator or subinvestigator in NCT04241068 and NCT05310071 (aducanumab, Biogen), NCT05399888 (BIIB080, Biogen), NCT03352557 (gosuranemab, Biogen), NCT05463731 (remternetug, Eli‐Lilly), NCT04592341 (gantenerumab, Roche), NCT03887455 (lecanemab, Eisai), NCT03828747 and NCT03289143 (semorinemab, Roche), NCT04619420 (JNJ‐63733657, Janssen – Johnson & Johnson), NCT04374136 (AL001, Alector), NCT04592874 (AL002, Alector), NCT04867616 (bepranemab, UCB Pharma), NCT04777396 and NCT04777409 (semaglutide, Novo Nordisk), NCT05469360 (NIO752, Novartis); is an unpaid national coordinator for NCT05564169 (masitinib, ABScience), NCT (AD04, ADvantage Therapeutics GmbH); has given unpaid lectures in symposia organized by Eisai and the Servier Foundation; and has been an unpaid expert for Janssen – Johnson & Johnson.

References

    1. GBD 2019 Dementia Forecasting Collaborators . Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019. Lancet Public Health. 2022;2667(21):1‐21. doi:10.1016/s2468-2667(21)00249-8 - DOI - PMC - PubMed
    1. Jack CRJ, AA Workgroup Members . Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. 2023. https://alz.org/media/Documents/scientific‐conferences/Clinical‐Criteria... - PMC - PubMed
    1. Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurol. 2021;20(6):484‐496. doi:10.1016/s1474-4422(21)00066-1 - DOI - PMC - PubMed
    1. Blocq P, Marinesco G. Sur les lésions et la pathogénie de l'épilepsie dite essentielle. La Sem Médicale. 1892;12:445‐446.
    1. Redlich E. Ueber miliare Sklerose der Hirnrinde bei seniler Atrophie. Jahrbücher für Psychiatr Und Neurol. 1898;17:208‐216.